Outcomes of pulmonary MDR-TB: Impacts of fluoroquinolone resistance and linezolid treatment

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 3127-3133

  Jeong, Byeong Ho ^a   Jeon, Kyeongman ^a   Park, Hye Yun ^a   Kwon, O Jung ^a   Lee, Kyung Soo ^a   Kim, Hong Kwan ^a   Choi, Yong Soo ^a   Kim, Jhingook ^a   Huh, Hee Jae ^a   Lee, Nam Yong ^a   Koh, Won Jung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; WORLD HEALTH ORGANIZATION; MIDDLE AGED; MULTIDRUG RESISTANCE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; LINEZOLID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84949032543     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv215     Document Type: Article

References (38)

1. WHO. Global Tuberculosis Report 2014. http://www.who.int/tb/publications/global_report/en.
2. Keshavjee S, Gelmanova IY, Farmer PE et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-9.
3. Kim DH, Kim HJ, Park SK et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 113-9.
4. Mitnick CD, Franke MF, Rich ML et al. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One 2013; 8: e58664.
5. Pietersen E, Ignatius E, Streicher EM et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383: 1230-9.
6. Velasquez GE, Becerra MC, Gelmanova IY et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis 2014; 59: 9-15.
7. Ahuja SD, Ashkin D, Avendano M et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
8. Falzon D, Gandhi N, Migliori GB et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-68.
9. Migliori GB, Sotgiu G, Gandhi NR et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-79.
10. Chang KC, Yew WW. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology 2013; 18: 8-21.
11. Daley CL, Caminero JA. Management of multidrug resistant tuberculosis. Semin Respir Crit Care Med 2013; 34: 44-59.
12. Falzon D, Jaramillo E, Schunemann HJ et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
13. KohWJ, Lee SH, Kang YA et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2013; 188: 858-64.
14. Dooley KE, Obuku EA, Durakovic N et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207: 1352-8.
15. Chang KC, Yew WW, Tam CM et al. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4097-104.
16. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-54.
17. Sotgiu G, Centis R, D'Ambrosio L et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-42.
18. Lee M, Lee J, Carroll MWet al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-18.
19. Kwon YS, Kim YH, Suh GYet al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
20. Nam HS, Koh WJ, Kwon OJ et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009; 33: 92-3.
21. Koh WJ, Kwon OJ, Gwak H et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drugresistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-91.
22. Koh WJ, Kang YR, Jeon K et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67: 1503-7.
23. WHO. Guidelines for the Progammatic Management of Drug-Resistant Tuberculosis. http://www.stoptb.org/assets/documents/resources/publications/technical/tb_guidelines.pdf.
24. WHO. Guidelines for the Progammatic Management of Drug-Resistant Tuberculosis. Emergency Update 2008. http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf.
25. WHO. Definitions and Reporting Framework for Tuberculosis - 2013 Revision. http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf.
26. Chiang CY, Caminero JA, Enarson DA. Reporting on multidrug-resistant tuberculosis: a proposed definition for the treatment outcome 'failed'. Int J Tuberc Lung Dis 2009; 13: 548-50.
27. Chiang CY, Van Deun A, Trebucq A et al. Treatment of multidrugresistant tuberculosis: definition of the outcome 'failure'. Int J Tuberc Lung Dis 2011; 15: 4-5.
28. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-60.
29. Dalton T, Cegielski P, Akksilp S et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-17.
30. Bastos ML, Hussain H, Weyer K et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-74.
31. Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-32.
32. Migliori GB, Eker B, Richardson MD et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-93.
33. Schecter GF, Scott C, True L et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
34. Singla R, Caminero JA, Jaiswal A et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-62.
35. Lange C, Abubakar I, Alffenaar JW et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
36. Zhang L, Pang Y, Yu X et al. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection 2014; 42: 705-11.
37. Chang KC, Yew WW, Cheung SWet al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother 2013; 57: 3445-9.
38. McGee B, Dietze R, Hadad DJ et al. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2009; 53: 3981-4.